Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18943Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Nikas, S. N. | en |
| dc.contributor.author | Voulgari, P. V. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T18:55:52Z | - |
| dc.date.available | 2015-11-24T18:55:52Z | - |
| dc.identifier.issn | 0770-3198 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18943 | - |
| dc.rights | Default Licence | - |
| dc.subject | Antibodies, Monoclonal/*adverse effects | en |
| dc.subject | Antibodies, Monoclonal, Humanized | en |
| dc.subject | Antirheumatic Agents/*adverse effects | en |
| dc.subject | Arthritis, Rheumatoid/*drug therapy | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Middle Aged | en |
| dc.subject | Urticaria/*chemically induced | en |
| dc.title | Urticaria and angiedema-like skin reactions in a patient treated with adalimumab | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1007/s10067-005-0197-7 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16421645 | - |
| heal.identifier.secondary | http://www.springerlink.com/content/p4kx2254886309xv/fulltext.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2007 | - |
| heal.abstract | Specific inhibition of the cytokine tumor necrosis factor alpha has resulted in significant clinical and laboratory improvement of patients with chronic inflammatory diseases of Th1 phenotype. Etanercept is a recombinant fusion protein of two p75 soluble receptors, while infliximab is a chimeric monoclonal antibody. Both have been considered to be immunogenic and cause various immune-mediated skin reactions. On the other hand, adalimumab, a human monoclonal antibody, was expected to cause little or no immune-mediated skin reactions. Herein, we report a patient with rheumatoid arthritis treated with adalimumab, who after the seventh injection, developed angiedema affecting the lips and face, as well as an urticaria-like skin reaction affecting the trunk. These reactions were followed by hypotension. The patient was treated appropriately and after 2 h, the rashes and the edema disappeared and the patient gradually recovered completely. Adalimumab was discontinued. | en |
| heal.journalName | Clin Rheumatol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Nikas-2007-Urticaria and angied.pdf | 79.72 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
